Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. 1999

B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
Division of Urology, CHUM-Campus St-Luc, Montréal, Québec, Canada.

OBJECTIVE We evaluate the long-term outcome of initial Ta grade 1 transitional cell carcinoma. METHODS A total of 152 patients with initial Ta grade 1 bladder tumor were followed for a mean of 76 months (range 6 to 241). Recurrence was defined as positive findings on cystoscopy or biopsy. Progression was defined as an increase in tumor grade or stage. RESULTS Tumor recurrence in 83 of 152 patients (55%) was noted within 12 months of followup in 38 patients (46%), between 12 and 24 in 11 (13%), and between 24 and 60 in 22 (27%). A significant number of recurrences (12, 14%) were diagnosed more than 60 months after the first tumor. Of 83 patients with recurrence 31 (37%) had progression, including 21 to grade 2 and 2 to grade 3 disease. Carcinoma in situ was diagnosed in 3 patients and 5 had muscle invasive disease. Progression occurred more than 24 months after initial diagnosis in 20 patients and more than 60 months after first tumor event (2 had carcinoma in situ and 2 had muscle invasive disease) in 12. CONCLUSIONS Ta grade 1 bladder transitional cell carcinomas have a high recurrence rate and progression is not uncommon. These findings warrant close long-term followup, even when in some settings the trend is to discontinue followup after 5 years without any abnormal findings.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
December 1986, Archives of surgery (Chicago, Ill. : 1960),
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
May 1988, The Journal of urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
July 2004, BJU international,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
May 2001, The Journal of urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
October 1959, The Journal of urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
June 2006, Hinyokika kiyo. Acta urologica Japonica,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
June 2012, Journal of pediatric urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
August 1996, British journal of urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
July 2004, The Journal of urology,
B Leblanc, and A J Duclos, and F Bénard, and J Côté, and L Valiquette, and J M Paquin, and F Mauffette, and R Faucher, and J P Perreault
January 1997, European urology,
Copied contents to your clipboard!